

SEPTEMBER 2021



DELIC CORP

Expanding always. In *all* ways.

(CSE: DELC) & (OTCQB: DELCF)

You Must Read This Before Continuing

This corporate presentation (“Presentation”) is confidential and contains proprietary non-public information regarding Delic Corp (“Delic”, the “Company”, “we”, “us” or “our”).

This Presentation is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities of the Company. The information contained herein has been prepared for the purpose of providing interested parties with general information to assist them in their evaluation of the Delic. Under no circumstances may the contents of this Presentation be reproduced, in whole or in part, in any form or forwarded or further redistributed to any other person. Any forwarding, distribution or reproduction of this document in whole or in part is unauthorized. By accepting and reviewing this document, you acknowledge and agree (i) to maintain the confidentiality of this document and the information contained herein, and (ii) to protect such information in the same manner you protect your own confidential information, which shall be at least a reasonable standard of care. Delic has not authorized anyone to provide prospective purchasers with additional or different information. In this Presentation all amounts are in Canadian dollars unless stated otherwise.

This Presentation constitutes “forward-looking statements,” within the meaning of applicable Canadian and United States securities laws. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, assumptions and analyses made by us regarding the future of our business, future plans and strategies, our operational results and other future conditions. These forward-looking statements appear in a number of places throughout this Presentation and can be identified by the use of words, such as “anticipates,” or “believes,” “budget,” “estimates,” “expects,” or “is expected,” “forecasts,” “intends,” “plans,” “scheduled,” or variations of such words and phrases or state that certain actions, events or results “may,” “might,” “will,” “would,” “could”, “should,” “continue,” or be taken, occur or be achieved. These forward-looking statements relate to, among other things, our future financial performance, financial condition, liquidity, levels of activity, performance, prospects, growth, goals or achievements or other future events. Although we base the forward-looking statements contained in this presentation on assumptions that we believe are reasonable, these forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual performance and financial results in future periods to differ materially from those anticipated in our forward-looking statements. Forward-looking statements do not take into account the effect that transactions or non-recurring or other special items announced or occurring after the statements are made have on our business. For example, the regulatory regime in which Delic operates, the novel COVID-19, they do not include the effect of asset impairments or other charges announced or occurring after the forward-looking statements are made. The financial impact of such transactions and non-recurring and other special items can be complex and necessarily depends on the facts particular to each of them. Despite a careful process to prepare and review the forward-looking statements, there can be no assurance that the underlying opinions, estimates, and assumptions will prove to be correct. The purpose of the forward-looking statements is to provide the reader with a description of management’s expectations regarding our anticipated future performance and may not be appropriate for other purposes. Furthermore, unless otherwise stated, the forward-looking statements contained in this Presentation are made as of the date of this Presentation and we do not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise unless required by applicable legislation or regulation. The forward-looking statements contained in this document are expressly qualified by this cautionary statement.

This Presentation also contains or references certain market, industry and peer group data which is based upon information from independent industry publications, market research, analyst reports and surveys and other publicly available sources. Although we believe these sources to be generally reliable, such information is subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other inherent limitations and uncertainties. We have not independently verified any of the data from third party sources referred to in this presentation and accordingly, the accuracy and completeness of such data is not guaranteed. This Presentation also includes forward-looking statements in respect of potential transactions that are not under contract and no certainty they will complete.

Delic has entered into a letter of intent with Ketamine Wellness Centers that includes binding exclusivity and the completion of the transaction is subject to negotiation of a definitive transaction document and customary closing conditions. There can be no assurance that the transaction between Delic and Ketamine Wellness Centers completes and Delic assumes no responsibility for the transaction not completing.




Mental health problems are widespread and getting worse, particularly after Covid-19

21% of adults in the US are experiencing high levels of psychological distress including 32% aged 18-29



Current popular pharmaceutical treatments aren't working for most.

40-71% of people who use antidepressants relapse. Response rate is around 30% & side effects are significant.



There's no scalable, trusted network of psychedelic clinics with a repeatable, non-habit forming and effective treatment process.




Ketamine has a 70% response rate in treatment resistant depression as soon as 24h

In 2019 esketamine was approved by the FDA as a fast-acting antidepressant.



The FDA granted **psilocybin** therapy as a breakthrough treatment for **depression**.

LSD & psilocybin have shown to reduce depression and anxiety for terminally ill patients.



The largest chain of trusted & accessible patient clinics with high profit margins and repeatable effective treatments for today and tomorrow's legal psychedelic wellness.

AUDIENCE & PATIENT NURTURING

Media

MEET DELIC
The Premier Psychedelic Wellness Event

RS
Free Digital Magazine

DELIC RADIO
PSYCHEDELIC WELLNESS
Podcast



Health

KETAMINE INFUSION CENTERS
Ketamine Clinics

Ketamine Wellness Centers
Ketamine Clinics

NATIONAL RETAIL CHAIN



DELIC LABS
Licensed Cannabis & Psilocybin Research Lab

Science

IP, R&D PRODUCTS

Delic owns and operates a self-sustaining umbrella of businesses to scale the impact and reach of treatment delivered through the the largest chain of psychedelic wellness clinics in the United States.

~32M people in the US have used psychedelics at least once

\$500B

annual US spend on
prescription drugs

\$238B

annual US spend
on mental health
treatments &
ancillary services

\$187.8B

US healthcare treatment
spend on mental health &
substance abuse
disorders in 2013

\$80B

estimated annual
spend on cigarettes

\$71B

2016 spend to
treat depressive
disorders


\$16B

anxiety disorder &
depression treatment
market

DELIC CORP will operate the largest chain of psychedelic wellness clinics in the country and a scalable ecosystem to increase revenue, profit margins and patient base.

Business Model

CLINIC FINANCIALS | CASE STUDY





DELIC CORP is the leading psychedelic wellness corporation, committed to bringing safe, legal and science-backed benefits to all.

Our self-sustaining and owned ecosystem of brands educate, influences, develops products and serves patients at scale.

With the **largest infrastructure of psychedelic wellness clinics** we are bringing psychedelic wellness to the masses by increasing patients at each clinic and increasing patient spend per visit.


MEDIA | AUDIENCE NURTURING

DELIC CORP

1. Captive audiences driven to clinics and owned platforms.
2. Provides high visibility of industry needs and developing trends.
3. Ability to educate and influence trends.

PODCAST

43+ episodes
Since Feb 2018
100k total streams



RealitySandwich.com

+5k original articles
1.4M views in 2020
+551 1st page Google rankings

EMAIL

+7k subscribers
115k unique opens*
11k clicks *in 2020



MEDIA | THE PREMIER PSYCHEDELIC WELLNESS EVENT

LAS VEGAS, NV @ AREA15

NOV
6&7
2021

**MEET
DELIC**

TICKETS ON SALE NOW!

EXPERIENCE
CONNECTION
EXPANSION

ATTENDEES

Expecting ~2k
Investors
Psychonauts
Entrepreneurs
Leading industry voices

SOCIAL

+18K followers
+141k reach/mo

EMAIL

+5k subscribers



MEDIA | THOUGHT LEADERSHIP

DELIC CORP is speaking to the mainstream.



MEET DELIC



DELIC CORP



MEET DELIC




DELIC CORP




MEET DELIC



DELIC CORP



SCIENCE | IP, R&D, Proven Products



We develop novel psychedelic products for markets that allow for legal psychedelics and treatment.

Rooted in science and evidence-based research that informs all product lines and ensures innovative treatments are safe and of the highest quality.

Delic Labs has operated profitably since its founding.

Delic Labs will focus on profit generating contracts as well as IP & novel compound development (patent development) licensing opportunities.

Delic Labs recently received its Section 56 Exemption granted by Health Canada, enabling CBDV to focus on research and intellectual property development with psilocybin.



Customers :

Biotech
Companies

Alcohol &
Tobacco


Instrument
Manufacturers

Cannabis
Producers

HEALTH | Clinic Services & Retail Presence

The U.S.'s largest retail and physical footprint will allow us to scale patient access and increase average spends.

As new treatments are legalized we will offer additional options with a keen focus on serving 2nd cities and the bulk of the population.



- Phoenix, AZ
- Tuscon, AZ
- Denver, CO
- Chicago, IL
- Minn/St Paul, MN
- Seattle, WA
- Dallas, TX
- Houston, TX
- Jacksonville, FL
- Las Vegas, NV

Delic has entered into a letter of intent with Ketamine Wellness Centers that includes binding exclusivity and the transaction is subject to completion.



- Bakersfield, CA
- Phoenix, AZ

15 new locations in development

Our team is comprised of proven leaders, executors and free thinkers. Strong industry networks, profitable businesses and successful prior exits ensure we are best positioned to capitalize on the burgeoning psychedelic wellness industry.

OPERATIONS



MATT STANG
CEO/CO-FOUNDER



CRO ADVISOR ADVISOR



JACKEE STANG
CCO/CO-FOUNDER



VP OF PROGRAMMING PRODUCER DIRECTOR OF DEVELOPMENT



MATHEW LEE
CFO



CFO PRESIDENT




ZAK GARCIA
CMO



CMO +4 YEARS SERVICE CONVOY COMMANDER IN IRAQ CMO



JOHN COLEMAN
VP of BD




CO-FOUNDER DEPARTMENT HEAD COO

DIRECTORS



MARTIN TOBIAS



CO-FOUNDER FOUNDER CEO



SASHKO DESPOTOVSKI



MANAGING DIRECTOR INVESTMENT DIRECTOR DIRECTOR OF M&A



KRAIG FOX



CEO & PRESIDENT SENIOR MANAGING DIRECTOR



PAUL ROSEN



CEO & CHAIRMAN EXECUTIVE CHAIRMAN PRESIDENT & CEO



DR. MARKUS ROGGEN



CEO & CO-FOUNDER RESEARCHER PROFESSOR

ADVISORS



SHEP GORDON



NY TIMES



FILM AGENT & PRODUCER



GREG CROWE

serendipity

CIO



DIRECTOR



DR. DAVE RABIN



CIO & CO-FOUNDER



ED & CO-FOUNDER



BOARD MEMBER



BARBARA BRANAMAN



CEO & FOUNDER



VP OF MARKETING & PRODUCT



VP/GM of HOSTING



KYLE SNOOK



SENIOR OPERATIONS EXECUTIVE



INFANTRY OFFICER



COO



GARYN ANGEL



FOUNDER



PRESIDENT



PRESIDENT



MICHAEL LOVITCH



FOUNDING PARTNER



BUSINESS MENTOR



PARTNER



DAVID BELSKY



CEO & FOUNDER



*All figures in \$CAD

Companies	Ticker	Business Model	Geography	Valuations	Quarterly Revenue	Open U.S. Locations	Locations in Development
Delic Corp	CSE:DELC	Clinics, media	USA	\$25M* <small>*upon conversion of multiple voting shares</small>	N/A	12	15
Field Trip Health	TSX:FTRP	Clinics, drug development	Canada, USA, Netherlands	\$358M	\$0.31M	5	5
Numinus Wellness	TSXV:NUMI	Clinics, drug development	Canada	\$175M	\$0.23M	4	N/A
Ketamine One	NMO:MEDI	Clinics, contact research	Canada	\$165M	N/A	1	4
Braxia	CSE:BRAX	Clinics, drug development	Canada	\$51M	\$0.28M ²	4	N/A
Novamind	CSE:NM	Clinics, contact research	USA	\$37M	\$1.85M ²	4	4

TIMELINE





CAPITAL STRUCTURE

CAP TABLE

Basic Issued & Outstanding	59,865,526
Options	5,003,887
Warrants	12,221,140
Fully Diluted	77,350,466
Multiple Voting Shares (upon conversion)	25,991,300*

*The Company has 259,913 multiple voting shares that convert at a 100-1 ratio. These shares are owned by insiders and are non listed.

(CSE: DELC) & (OTCQB: DELCF)

Alex Howe

(202) 271-7999

alex@deliccorp.com

